Acalatinib/Acalatinib: Kangerqi brings new hope for cancer treatment

Concoqi, behind the brand name represents Acalabrutinib/Acalabrutinib, an innovative drug that was officially approved for marketing in China in May 2023. It is mainly used to treat adult patients with mantle cell lymphoma (MCL) who have experienced one or more treatments, providing them with a new treatment option. Recently, the drug was also approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), demonstrating its broad therapeutic potential.

Acotinib belongs to a class of drugs calledBTK inhibitors, which effectively prevent the growth and spread of malignant tumor cells by inhibiting the activity of B cell receptor tyrosine kinase (BTK). BTK plays a crucial role in the signaling process of B cells, especially in some B-cell lymphomas, and its overactivity may lead to rapid proliferation and survival of tumor cells. Acotinib precisely inhibits the function of BTK and cuts off this key signaling pathway, thereby achieving the purpose of anti-cancer.

For patients, the emergence of acotinib is undoubtedly good news. It provides new treatment strategies for such patients and is expected to significantly improve their survival conditions and quality of life. However, like other drugs, acotinib needs to be used correctly under the guidance of a doctor. The specific dosage and treatment duration should be individualized based on the patient's specific condition. At the same time, patients should also be wary of possible adverse drug reactions, such as bleeding, infection, or diarrhea. In the event of serious adverse reactions, seek medical attention immediately to ensure safety.